MAVERICK

The MaverickDiagnostic System (MDS) uses

silicon chip-based photonic ring resonator

technology to perform multiple simultaneous

rapid tests on a small volume of whole

blood or serum.  The system is cloud-connected

for assay protocol retrieval and clinical

oversight.

Maverick™ Immunoassay Analyzer

 

  • Benchtop solution available for On-Site or Core Laboratory testing as well as integrated in Merlin
  • Runs four patients simultaneously
  • Runs up to 26 tests on a single drop of blood
  • 250 patients/day
  • High sensitivity and specificity
  • Cloud-connected with CLIA/CAP pathology oversight
  • Dimensions:
    11” high X 16″ wide X 23″ deep

Photonic Ring Resonator Technology

 

Genalyte has developed multiplex assay detection technology based on silicon photonics that uses ring resonance to measure binding of macromolecules to sensors on a miniature silicon chip.  The MaverickDiagnostic System detects changes in resonance wavelength as macromolecules, such as autoantibodies, bind to their respective antigens that are bound to the chip; eliminating the need for fluorescent, luminescent, or radioactive labels used in other immunoassay formats.

SARS-CoV-2 Multi-Antigen Serology Panel

 

 Genalyte’s SARS-CoV-2 antibody test measures reactivity levels for 26 IgG and IgM antibody targets with market leading performance.

Tested by Northshore University, Mayo Clinic, and Scripps, Genalyte’s SARS-CoV-2 antibody test had the highest sensitivity and specificity as compared to central lab machines. 

How It Works

Watch Maverick™ Technology In Action

31 Patent Issued and 17 Pending

Our proprietary Marverick™ Diagnostic System (MDS) has 31 patents issued and 17 patents pending worldwide.

 

FDA Clearance and EUA Authorization 

The MaverickTM Diagnostic System (MDS) received FDA clearance for RNP (ribonuceloprotein) assay in October 2019.

In addition, the MaverickTM Diagnostic System (MDS) received Emergency Use Authorization (EUA) by the FDA for SARS-CoV-2 Multi-Antigen Serology Panel in October 2020

Improving overall patient care

In order to improve overall patient care with rapid laboratory diagnostics, Genalyte became a clinical diagnostic provider receiving CLIA certification and CAP accreditation in 2017

Science

Publications • White Papers • Brochures & Posters

Onsite lab result under 30 minutes

Move Data, Not Blood